The European Journal of Health Economics

2002 - 2025

Current editor(s): J.-M.G.v.d. Schulenburg

From:
Springer
Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ)
Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 4, issue 4, 2003

Economic burden of obesity and its complications in Germany pp. 248-253

Beate Sander and Rito Bergemann

Cost-effectiveness of fondaparinux vs. enoxaparin as venous thromboembolism prophylaxis in Sweden pp. 254-262

Jonas Lundkvist, David Bergqvist and Bengt Jönsson

Should one use smokeless tobacco in smoking cessation programs? pp. 263-270

Mikael Bask and Maria Melkersson

A Markov model of treatment of newly diagnosed epilepsy in the UK pp. 271-278

E. Remák, J. Hutton, M. Price, K. Peeters and I. Adriaenssen

Financial incentives and the supply of laboratory tests pp. 279-285

Fredrik Carlsen, Jostein Grytten and Irene Skau

Health care reform in six Central European countries pp. 286-291

Mark Nuijten, Agota Szende, Jozsef Kosa, Zsolt Mogyorosy, Boris Kramberger, Karel Nemecek, Dominik Tomek, Stjepan Oreskovic and Monika Laskowska

An exponential representation of health state utility pp. 292-294

Michael Happich and Axel Muehlbacher

Testing assumptions of quality-adjusted life-year calculations pp. 295-295

Ariel Béresniak

Project of Polish guidelines for conducting pharmacoeconomic evaluations in comparison to international health economic guidelines pp. 296-303

Ewa Orlewska and Piotr Mierzejewski

Modeling risk-adjusted capitation rates for Umbria, Italy pp. 304-312

Elaine Yuen, Daniel Louis, Paolo Loreto and Joseph Gonnella

The lag between effectiveness and cost-effectiveness evidence of new drugs pp. 313-318

Boyka Stoykova, Michael Drummond, Marco Barbieri and Jos Kleijnen

Measles dynamics and vaccination diffusion pp. 319-326

Laurent Coudeville

An overview of the Greek pharmaceutical market pp. 327-333

V. Kontozamanis, E. Mantzouneas and Chrysostomos Stoforos

Volume 4, issue 3, 2003

When should decision-analytic modeling be used in the economic evaluation of health care? pp. 143-150

Uwe Siebert

Pharmaceutical expenditure in Spain: evolution and cost containment measures during 1998–2001 pp. 151-157

Josep Darbà

A fuzzy logic approach toward solving the analytic enigma of health system financing pp. 158-175

Dov Chernichovsky, Arkady Bolotin and David Leeuw

Scale of reference bias and the evolution of health pp. 176-183

Wim Groot

Is therapeutic innovation responsible for the increase in drug expenditure? pp. 184-194

Philippe Cavalié

Time to disable DALYs? pp. 195-202

Carl Hampus Lyttkens

Costs and effectiveness of a syringe distribution and needle exchange program for HIV prevention in a regional setting pp. 203-208

Juan Cabasés and Eduardo Sánchez

Economic evaluation of human papillomavirus screening in Germany pp. 209-215

T. Mittendorf, K. Petry, T. Iftner, W. Greiner and J. Schulenburg

Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK pp. 216-221

Mike Aristides, Michael Lees, Nick Botwood, Jan McKendrick, Deborah Stephenson and Nikos Maniadakis

A single European currency for EQ-5D health states pp. 222-231

Wolfgang Greiner, Tom Weijnen, Martin Nieuwenhuizen, Siem Oppe, Xavier Badia, Jan Busschbach, Martin Buxton, Paul Dolan, Paul Kind, Paul Krabbe, Arto Ohinmaa, David Parkin, Montserat Roset, Harri Sintonen, Aki Tsuchiya and Frank Charro

The efficiency of treatment strategies of general practitioners pp. 232-238

Matthias Staat

Commentary on Coyle et al., "The assessment of the economic return from controlled clinical trials" pp. 239-240

Jon Karnon, A. Brennan and J. Chilcott

Volume 3, issue 3, 2002

Measuring health system performance pp. 145-148

P.C. Smith

Budget impact model for determining the costs of introducing inhaled salmeterol/fluticasone propionate combination for the management of persistent asthma in France pp. 149-155

B. Detournay, C. Pribil, C. Jourdanne and M. Price

Disease progression in amyotrophic lateral sclerosis pp. 156-165

M. Tavakoli

Costs of toxicity during chemotherapy with CHOP, COP/CVP, and fludarabine pp. 166-172

M. Herold and K. Hieke

A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia pp. 173-179

K. Hansen, C. François, M. Toumi and C. Lançon

Modelling the costs and effects of leflunomide in rheumatoid arthritis pp. 180-187

G. Kobelt, P. Lindgren and A. Young

Medical savings accounts: a core feature of Singapore's health care system pp. 188-195

W. von Eiff, T. Massoro, Y. O. Voo and R. Ziegenbein

Methodological guidelines for conducting economic evaluation of healthcare interventions in Hungary: a Hungarian proposal for methodology standards pp. 196-206

Ágota Szende, Z. Mogyorósy, N. Muszbek, J. Nagy, G. Pallos and C Dözsa

Restructuring of the healthcare system and the diffusion of telemedicine pp. 207-214

M. Kerleau and N. Pelletier-Fleury

Pricing and reimbursement of pharmaceuticals in Norway pp. 215-220

A. Hågå and J. M. Sverre

Volume 3, issue 2, 2002

Genetic testing and the health care system pp. 73-76

Oliver Schöffski

Burden of illness imposed by severe sepsis in Germany pp. 77-82

A. Schmid, H. Burchardi, J. Clouth and H. Schneider

Risk-adjusted capitation funding models for chronic disease in Australia: alternatives to casemix funding pp. 83-93

K. M. Antioch and M.K. Walsh

The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom pp. 94-102

J. Bonastre, C. Le Pen, P. Anderson, A. Ganz, P. Berto and G. Berdeaux

Reputation, public information, and physician adoption of an innovation pp. 103-110

J. G. Smythe

Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine pp. 111-119

Lukas Radbruch, K. Lehmann, H.-H. Gockel, D. Neighbors and G. Nuyts

Association of time preference for health with age and disease severity pp. 120-124

K. Stavem, I. S. Kristiansen and J. A. Olsen

Erratum to: Does health technology assessment benefit health services and politics? pp. 124-124

H. Sigmund and F.B. Kristensen

Is EQ-5D a valid measure of HRQoL in patients with movement disorders? pp. 125-130

S. Ghislandi, G. Apolone, L. Garattini and I. Ghislandi

Developing a scoring system to quality assess economic evaluations pp. 131-136

J. G. Gonzalez-Perez

Time for a change in drug licensing requirements? pp. 137-138

Michael F. Drummond

Commentary pp. 138-138

Johann Graf von der Schulenburg

Commentary pp. 139-139

Bengt Jönsson

Time for a change in drug pricing: Going downstream pp. 140-141

Gérard Pouvourville

Drug licensing requirements are changing! pp. 141-142

F. Lekkerkerker and F. Rutten

A final comment pp. 142-142

Michael F. Drummond

Volume 3, issue 1, 2002

Costing hospital activity: the experience with healthcare resource groups in England pp. 3-9

Andrew Street and D. Dawson

Comparing the results of applying different methods of eliciting time preferences for health pp. 10-16

Dorte Gyrd-Hansen

Devolved budgetary responsibility in primary care pp. 17-25

P. Wilton and R. D. Smith

Integrating cost-effectiveness evidence into clinical practice guidelines in Australia for acute myocardial infarction pp. 26-39

K. M. Antioch, G. Jennings, M. Botti, R. Chapman and V. Wulfsohn

Priorities and Prospect Theory pp. 40-46

M. Happich and B. Mazurek

Adapting portfolio theory for the evaluation of multiple investments in health with a multiplicative extension for treatment synergies pp. 47-53

J. F. P. Bridges, M. Stewart, M. T. King and K. van Gool

Does health technology assessment benefit health services and politics? pp. 54-58

H. Sigmund and F. B. Kristensen

Overview of economic evaluation of positron-emission tomography pp. 59-65

A. Müller, D. Stratmann-Schöne, T. Klose and Reiner Leidl

Pricing and reimbursement of drugs in Sweden pp. 66-70

J. Lundkvist

Report on the 4 th ISPOR European Annual Meeting in November 2001 in Cannes, France pp. 71-71

Wolfgang Greiner